Standout Papers

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell l... 2017 2026 2020 2023 335
  1. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial (2017)
    Corinne Faivre‐Finn, M. Snee et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 4 from Science/Nature 98 standout
Sub-graph 1 of 22

Citing Papers

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
17 intermediate papers

Works of R. McMenemin being referenced

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
2017 Standout
Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I
2002

Author Peers

Author Last Decade Papers Cites
R. McMenemin 654 266 493 289 42 1.2k
R. Tarabuzzi 807 331 456 145 41 1.2k
Sabine Haufe 634 157 433 491 31 1.5k
Phillip J. Koo 409 231 321 137 57 1.1k
Kazuhiro Nagayama 573 320 341 130 69 1.2k
Göran Ahlgren 917 189 168 90 45 1.2k
Elliot K. Fishman 447 556 227 133 43 1.3k
Najeeb Mohideen 1023 295 373 116 36 1.4k
Rodolfo Núñez 651 346 487 212 37 1.5k
Shetal N. Shah 542 233 155 271 47 1.4k
Hedy Mameghan 591 411 251 42 54 1.2k

All Works

Loading papers...

Rankless by CCL
2026